MONMOUTH JUNCTION, N.J.,
May 26, 2015 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care
immunotherapy commercializing its CytoSorb® extracorporeal cytokine
adsorber to purify blood and control severe inflammation, announced
that Dr. Phillip Chan, Chief
Executive Officer, will make an overview presentation at the LD
Micro Conference on Monday, June 1,
2015 at 10:30AM PDT /
1:30PM EDT at the Luxe Hotel in
Los Angeles, California. Dr.
Chan will also be available to participate in one-on-one meetings,
made by appointment, with investors who are registered to attend
the conference.
Date:
|
|
|
Monday, June 1,
2015
|
Time:
|
|
|
10:30AM PDT
(1:30PM EDT)
|
Location:
|
|
|
Luxe Hotel, Los
Angeles, CA
|
About LD Micro
LD Micro is an investment newsletter firm that focuses on
finding undervalued companies in the micro-cap space. Since
2002, the firm has published reports on select companies throughout
the year. The firm also hosts the LD Micro Main Event in
December. It is a non-registered investment advisor.
For more information, please contact 408-457-1042 or
visit www.ldmicro.com.
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to control severe
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is
the cause of nearly half of all deaths in the intensive care unit,
with little to improve clinical outcome. CytoSorb®, the
Company's flagship product, is approved in the European Union with
distribution in 29 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used
during and after cardiac surgery to remove inflammatory mediators,
such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's
websites: http://www.cytosorbents.com and
http://www.cytosorb.com
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 31, 2015, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and
Twitter
CytoSorbents Contact:
Amy Vogel
Investor Relations
(732) 329-8885 ext. *825
avogel@cytosorbents.com
Investor Contact:
Lee
Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
Public Relations Contact:
Melanie Sollid-Penton
The Ruth Group
646-536-7023
msollid@theruthgroup.com
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-ld-micro-invitational-on-june-1st-300088358.html
SOURCE CytoSorbents Corporation